跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/JPRN-jRCTs071220105
JPRN-jRCTs071220105招募中2 期

Effects of synbiotics supplementation on chronological change of gut microbiome and cancer immunotherapy in Treatment-naive non-small cell lung cancer patients: a double-blind randomized controlled study - SYNCOPATION study

Shoji Fumihiro0 个研究点目标入组 60 人开始时间: 2023年2月10日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
60
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable（—）
性别
All

入选标准

  • •1) Patients with histologically or cytologically diagnosed Stage IV (T any, N any, M1a or M1b or M1c (UICC 8th)) non-small cell lung cancer or postoperative recurrence not eligible for radical therapy.
  • •PD-L1 protein expression and histology (squamous or non-squamous) are not required.
  • •2) Patients not eligible for epidermal growth factor receptor (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, or c-ros oncogene (ROS1) inhibitors.
  • •3) Patients scheduled to receive either pembrolizumab monotherapy or the following pembrolizumab combination therapy
  • •Pembrolizumab monotherapy: PD-L1 positive (Tumor Proportion Score (TPS)>= 50% (strongly positive))
  • •Pembrolizumab + pemetrexed + cisplatin/ carboplatin: non-squamous non-small cell lung cancer
  • •Pembrolizumab + nab-Paclitaxel/paclitaxel + carboplatin: Squamous cell non-small cell lung cancer
  • •4) Patients with at least one measurable lesion based on RECIST version 1.1 on imaging test within 28 days prior to enrollment.
  • •However, bone lesions, cystic lesions, and lesions with a history of topical treatment such as radiotherapy are considered as non-measurable lesions.
  • •5) Patients untreated with chemotherapy including molecular-targeted drugs and cancer immunotherapy.
  • •However, a history of preoperative/postoperative adjuvant therapy is acceptable if completed at least 6 months prior to the date of enrollment.
  • •6) Patients deemed able to cooperate in the collection and submission of fecal specimens and recording of patient diaries.
  • •7) Patients who can orally ingest synbiotic foods (synprotec or placebo food).
  • •8) Patients who are at least 20 years of age at the time of consent
  • •9) Patients expected to survive more than 3 months
  • •10) Patients with ECOG Performance Status 0 or 1
  • •11) Patients who meet the following criteria for major organ function within 14 days prior to enrollment (based on the date of enrollment, the same day of prior two weeks is acceptable).
  • •If there are multiple test results within the period, the latest one will be used.
  • •Test item Reference value
  • •Neutrophil count >=1,500/mm3
  • •Platelet count >=100,000 / mm3
  • •Hemoglobin >=9.0 g/dL or >=5.6 mmol/L (after 4 weeks of transfusion)
  • •AST/ALT =<2.5 x ULN (if liver metastases present=<5.0 x ULN)
  • •Total bilirubin =<1.5 x ULN
  • •Creatinine =<1.5 x ULN
  • •If creatinine >1.5 x ULN, if creatinine clearance >= 60 mL/min
  • •12) Patients who have been fully informed of the contents of this study and have given their written consent.

排除标准

  • •1) Patients who are taking medicines containing prebiotics and probiotics on a daily basis, or taking supplements (including synprotec) at the time of informed consent.
  • •2) Patients who are allergic to galactooligosaccharides or milk.
  • •3) Patients with active infection of HIV, HBV, HCV, or syphilis.
  • •However, the following are acceptable for enrollment
  • •HBV: Patients who are HBs antibody-positive, HBc antibody-positive, or HBs antigen-positive, but whose viral load is less than sensitivity and who have inactive hepatitis may be enrolled.
  • •HCV: Antibody-positive patients with inactive hepatitis may be enrolled.4) Patients participating in other clinical trials or clinical studies.
  • •5) Patients who have received radiation therapy to the lungs exceeding 30 Gy within 4 weeks of the date of consent.
  • •6) Patients who completed palliative radiation therapy within 7 days prior to enrollment in this study.
  • •7) Patients who have received a live vaccine within 30 days prior to enrollment in this study.
  • •8) Patients with clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or carcinomatosis.
  • •9) Patients with a history of malignancy other than non-small cell lung cancer, except for those who have been relapse-free for 5 years after the start of curative treatment.
  • •10) Patients with active central nervous system (CNS) metastases or cancerous meningitis. However, patients who are asymptomatic and clinically stable may be enrolled.
  • •11) Patients with a history of severe hypersensitivity reactions to other monoclonal antibodies.
  • •12) Patients with hypersensitivity to cisplatin, carboplatin, pemetrexed, nab-paclitaxel and paclitaxel.
  • •13) Patients with Grade >=2 peripheral neuropathy according to CTCAE version 5.0.
  • •14) Patients with active autoimmune disease requiring systemic treatment within the past 2 years.
  • •15) Patients chronically taking systemic steroids.
  • •16) Patients with psychiatric, dementia, or substance abuse disorders that have been determined to have the potential to affect their participation in this study.
  • •17) Patients with ascites or pleural effusions requiring treatment. However, patients who are clinically stable with treatment may be eligible for enrollment.
  • •18) Patients with complication of interstitial lung disease or a history of pnemonitis requiring oral/intravenous corticosteroid therapy.
  • •19) Pregnant patients, lactating patients, or patients who wish to have their own or their partner pregnancy during the period of this study.
  • •20) Other patients who are judged by the principal investigator or sub-investigator to be inappropriate to participate in this study.

研究者

发起方
Shoji Fumihiro

相似试验

已完成
不适用
The Effects of Synbiotics, Branched Chain Amino Acids on Hepatic EncephalopathyHepatic encephalopathy in patients with cirrhosisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonDiet and Nutrition - Other diet and nutrition disorders
ACTRN12610001021066Royal Prince Alfred Hospital80
已完成
不适用
The effect of synbiotic supplement on improvement of diabetics overweight status.Diabetes.Non-insulin-dependent diabetes mellitus
IRCT2016062628386N2Vice chancellor for research, Alborz University of Medical Sciences100
招募中
3 期
The effect of Synbiotic on aggressio
IRCT20091114002709N53Iran University of Medical Sciences100
招募中
1 期
Effect of synbiotic in cystic fibrosisCystic fibrosis.E84.0 Cystic fibrosis with pulmonary manifestations
IRCT2017011732004N1Pediatric health research center40
招募中
3 期
The effect of probiotic supplementation on pregnancy outcomes in mothers with mild preeclampsiamild preeclampsia.Mild to moderate pre-eclampsiaO14.0
IRCT20110606006709N20Tabriz University of Medical Sciences128